I AM VERY BULLISH ON $TMDX
Here's a recap of the most exciting parts of Investor Day today
1. Management are very confident they will achieve 10,000 transplants. That's the publicly stated goal but they have sites FAR larger than that.
2. Currently, we're only utilizing less than 20% of lungs, less than 30% of hearts, and ~60% livers. This means the vast majority of the donor pool is completely untapped.
3. There's a lot of $TransMedics Group, Inc.(TMDX)$ competitors out there that are not solving the issue of ischemia. Ischemic damage is the damage that occurs when there's no blood supply to an organ. The longer this happens for, the increased chance of morbidity. There's no competitor out there that has a product that is able to eliminate ischemic damage AND bring the organ to the patient. $TMDX have the only multi-organ PORTABLE perfusion technology on the planet.
4. $TMDX data shows they have reduced PGD (primary graft dysfunction) by 50% in lung, 65% in heart and liver, and reduced ischemic biliary complication by 84% in liver transplants.
5. $TMDX showcased their Command Center which is the heartbeat of the logistics business. This is the place that $TMDX coordinate their missions (air and ground) to ensure that organs get to their destinations in as quick a time as possible. It shows how $TMDX have FULL control over their entire business operation. It's one of the largest moats for a small cap company in the entire market.
6. Data has shown that ischemic biliary complications for 4,300 liver transplants is at just 1.7% using $TMDX transported organs.
7. Morning transplants are a key driver of organ success and the financials. Morning transplants have not previously been possible but with $TMDX logistics capabilities they are.
8. There's 3 next gen programs that will lead to huge growth in 2025 all using the leverage that the big investment into the logistics network in 2024 allowed for. These are the next gen lung program, the next gen heart clinical program, and the NOP network which will be a digital ecosystem with full transparency to all stakeholders involved.
9. $TMDX have eliminated all edema up to 24 hours in lung transplants. This is something that they had not managed to solve in 2024. This was shared to 175 lung transplant surgeons 2 weeks ago in Boston so this is all very new and an exciting development for 2025.
10. Management also introduced Envision, an ecosystem that manages all aspects of of organ procurement to transplantation. It also includes all financial administration work such as case count for OCS, cost of OCS, an automatic billing. More streamlining. More efficiency.
11. Management continuously touched on the fact that $TMDX will be an international company. The TAM is ginormous.
12. 2025 development will focus on Kidney with launch in 2029 post FDA clinical trials in 2027. This adds ~50,000 transplants a year to the TAM.
13. Management discussed their next gen OCS vision which completely reimagines how OCS works to allow $TMDX to do upwards of 30,000 transplants a year. Everything will be highly automated and high tied to the cloud which will drive huge financial efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
